New narcolepsy drug enters first human safety tests

NCT ID NCT07613710

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new drug called Lu AH69593 to see if it is safe and how the body handles it. The study includes healthy volunteers and people with narcolepsy. Researchers will monitor side effects and measure drug levels in the blood, including how food affects absorption.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Lu AH69593

What this could lead to

If successful, this could point toward a new treatment option to help manage narcolepsy symptoms.

What could go wrong

This is a very early Phase 1 trial focused on safety, not effectiveness. The drug may not work or could have side effects. Results may not apply to all patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NARCOLEPSY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

narcolepsy narcolepsy-cataplexy syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CRST, Clinical Research Services Turku

    RECRUITING

    Turku, 20520, Finland

  • Terveystalo Helsinki, Sleep Clinic

    RECRUITING

    Helsinki, 00380, Finland